Technology

Selecta Biosciences

$3.45
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.08 (+2.38%) Today
+$0.01 (+0.29%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell SELB and other stocks, options, and ETFs commission-free!

About SELB

Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. It produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm's proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA. The listed name for SELB is Selecta Biosciences, Inc. Common Stock.

CEO
Carsten Brunn
Employees
39
Headquarters
Watertown, Massachusetts
Founded
2007
Market Cap
380.47M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
1.57M
High Today
$3.48
Low Today
$3.32
Open Price
$3.37
Volume
986.23K
52 Week High
$4.83
52 Week Low
$1.42

Collections

SELB Earnings

-$0.37
-$0.25
-$0.12
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 11, Pre-Market

You May Also Like

UWM
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure